290 related articles for article (PubMed ID: 22579287)
1. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
Shan Y; Eastwood MP; Zhang X; Kim ET; Arkhipov A; Dror RO; Jumper J; Kuriyan J; Shaw DE
Cell; 2012 May; 149(4):860-70. PubMed ID: 22579287
[TBL] [Abstract][Full Text] [Related]
2. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
Zhang X; Gureasko J; Shen K; Cole PA; Kuriyan J
Cell; 2006 Jun; 125(6):1137-49. PubMed ID: 16777603
[TBL] [Abstract][Full Text] [Related]
3. Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.
Sakai K; Arao T; Shimoyama T; Murofushi K; Sekijima M; Kaji N; Tamura T; Saijo N; Nishio K
FASEB J; 2006 Feb; 20(2):311-3. PubMed ID: 16373402
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.
Ruan Z; Kannan N
Biochemistry; 2015 Jul; 54(27):4216-25. PubMed ID: 26101090
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulation reveals structural and thermodynamic features of kinase activation by cancer mutations within the epidermal growth factor receptor.
Wan S; Coveney PV
J Comput Chem; 2011 Oct; 32(13):2843-52. PubMed ID: 21717480
[TBL] [Abstract][Full Text] [Related]
6. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
7. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization.
Aifa S; Aydin J; Nordvall G; Lundström I; Svensson SP; Hermanson O
Exp Cell Res; 2005 Jan; 302(1):108-14. PubMed ID: 15541730
[TBL] [Abstract][Full Text] [Related]
8. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X; Sun Y; Wang H; Lu S
Amino Acids; 2014 Jul; 46(7):1635-48. PubMed ID: 24658966
[TBL] [Abstract][Full Text] [Related]
9. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
[TBL] [Abstract][Full Text] [Related]
10. Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase.
Ge G; Wu J; Wang Y; Lin Q
Biochem Biophys Res Commun; 2002 Jan; 290(3):914-20. PubMed ID: 11798160
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics of the asymmetric dimers of EGFR: simulations on the active and inactive conformations of the kinase domain.
Songtawee N; Bevan DR; Choowongkomon K
J Mol Graph Model; 2015 May; 58():16-29. PubMed ID: 25805329
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms for oncogenic activation of the epidermal growth factor receptor.
Zandi R; Larsen AB; Andersen P; Stockhausen MT; Poulsen HS
Cell Signal; 2007 Oct; 19(10):2013-23. PubMed ID: 17681753
[TBL] [Abstract][Full Text] [Related]
14. Homology models of the mutated EGFR and their response towards quinazoline analogues.
Kotra S; Madala KK; Jamil K
J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
[TBL] [Abstract][Full Text] [Related]
15. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations.
Liu B; Bernard B; Wu JH
Proteins; 2006 Nov; 65(2):331-46. PubMed ID: 16927343
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
Carey KD; Garton AJ; Romero MS; Kahler J; Thomson S; Ross S; Park F; Haley JD; Gibson N; Sliwkowski MX
Cancer Res; 2006 Aug; 66(16):8163-71. PubMed ID: 16912195
[TBL] [Abstract][Full Text] [Related]
17. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
18. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
Kobayashi S; Ji H; Yuza Y; Meyerson M; Wong KK; Tenen DG; Halmos B
Cancer Res; 2005 Aug; 65(16):7096-101. PubMed ID: 16103058
[TBL] [Abstract][Full Text] [Related]
19. Conformational regulation of the EGFR kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics study.
Mustafa M; Mirza A; Kannan N
Proteins; 2011 Jan; 79(1):99-114. PubMed ID: 20938978
[TBL] [Abstract][Full Text] [Related]
20. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Okabe T; Okamoto I; Tamura K; Terashima M; Yoshida T; Satoh T; Takada M; Fukuoka M; Nakagawa K
Cancer Res; 2007 Mar; 67(5):2046-53. PubMed ID: 17332333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
